A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study

Critical Care Medicine

Volumn 38, Issue 8, 2010, Pages 1651-1664

  Kumar, Anand ^a,b   Safdar, Nasia ^c   Kethireddy, Shravan ^a   Chateau, Dan ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

antibiotic; combination therapy; critically ill; infectious diseases; outcome; sepsis; septic shock; serious infection

Indexed keywords

AMIKACIN; AMPICILLIN; BETA LACTAM; CARBENICILLIN; CEFOPERAZONE; CEFOTAXIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MACROLIDE; MEROPENEM; MEZLOCILLIN; NETILMICIN; PIPERACILLIN; TOBRAMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COCHRANE LIBRARY; EMBASE; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 77954959272     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181e96b91     Document Type: Article

References (113)

1. Darras-Joly C, Bedos JP, Sauve C, et al: Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and-tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1996; 40:2147-2151
2. Calandra T, Glauser MP: Immunocompromised animal models for the study of antibiotic combinations. Am J Med 80:45-52, 1986
3. Kumar A, Mensing J, Zelenitsky S, et al: Effect of antibiotic sequence on blood bacterial counts in a rat model of E. coli peritonitis/septic shock. ICAAC Proc 2004; 26: A-1296
4. Anderson ET, Young LS, Hewitt WL: Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978; 24:45-54
5. De Jongh CA, Joshi JH, Newman KA, et al: Antibiotic synergism and response in gramnegative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80:96-100
6. Bouza E, Munoz P: Monotherapy versus combination therapy for bacterial infections. Med Clin North Am 2000; 84: 1357-1389
7. Safdar N, Handelsman J, Maki DG, et al: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527
8. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668-679
9. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
10. Boissel JP, Collet JP, Lievre M, et al: An effect model for the assessment of drug benefit: Example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol 1993; 22:356-363
11. Antman EM, Seelig MS, Fleischmann K, et al: Magnesium in acute myocardial infarction: Scientific, statistical, and economic rationale for its use. Cardiovasc Drugs Ther 1996; 10:297-301
12. Schmid CH, Lau J, McIntosh MW, et al: An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med 1998; 17:1923-1942
13. Vidal L, Gafter-Gvili A, Borok S, Fraser A, et al: Efficacy and safety of aminoglycoside monotherapy: Systematic review and metaanalysis of randomized controlled trials. J Antimicrob Chemother 2007; 60:247-257
14. Crabtree TD, Pelletier SJ, Gleason TG, et al: Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients. Arch Surg 1999; 134: 1293-1298
15. DerSimonian R: Meta-analysis in the design and monitoring of clinical trials. Stat Med 1996; 15:1237-1248
16. Valles J, Rello J, Ochagavia A, et al: Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-1624
17. Brun-Buisson C, Meshaka P, Pinton P, et al: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588
18. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 20 N Engl J Med 2003; 348:1546-1554
19. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560
20. Egger M, Davey SG, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634
21. Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573
22. van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21:589-624
23. Sculier JP, Coppens L, Klastersky J: Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of Gram-negative bronchopneumonia. J Antimicrob Chemother 1982; 9:63-68
24. Karnad A, Alvarez S, Berk SL: Pneumonia caused by gram-negative bacilli. Am J Med 1985; 79:61-67
25. Vazquez EG, Mensa J, Martinez JA, et al: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24:190-195
26. Dwyer R, Ortqvist A, Aufwerber E, et al: Addition of a macrolide to a-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 518-521
27. Baddour LM, Yu VL, Klugman KP, et al: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-444
28. Rodriguez A, Mendia A, Sirvent JM, et al: Combination antibiotic therapy improves survival in patients with communityacquired pneumonia and shock. Crit Care Med 2007; 35:1493-1498
29. Chow JW, Fine MJ, Shlaes DM, et al: Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-590
30. Kim BN, Lee SO, Choi SH, et al: Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: An analysis of 249 cases caused by Citrobacter, Enterobacter, and Serratia species. Int J Antimicrob Agents 2003; 22:106-111
31. Chokshi R, Restrepo MI, Weeratunge N, et al: Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae communityacquired pneumonia. Eur J Clin Microbiol Infect Dis 2007; 26:447-451
32. Martinez JA, Horcajada JP, Almela M, et al: Addition of a macrolide to a beta-lactambased empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-395
33. Damas P, Garweg C, Monchi M, et al: Combination therapy versus monotherapy: A randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care 2006; 10:R52
34. Korvick JA, Bryan CS, Farber B, et al: Prospective observational study of Klebsiella bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992; 36:2639-2644
35. Cometta A, Baumgartner JD, Lew D, et al: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38: 1309-1313
36. Kreger BE, Craven DE, McCabe WR: Gramnegative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344-355
37. McCue JD: Improved mortality in gramnegative bacillary bacteremia. Arch Intern Med 1985; 145:1212-1216
38. Bouza E, Garcia DLT, Erice A, et al: Serratia bacteremia. Diagnos Microbiol Infect Dis 1987; 7:237-247
39. Carbon C, Auboyer C, Becq-Giraudon B, et al: Cefotaxime (C) vs cefotaxime amikacin (C A) in the treatment of septicemia due to enterobacteria: A multicenter study. Chemioterapia 1987; 6(2 Suppl):367-368
40. McCue JD: Gram-negative bacillary bacteremia in the elderly: Incidence, ecology, etiology, and mortality. J Am Geriatr Soc 1987; 35:213-218
41. Kuikka A, Sivonen A, Emelianova A, et al: Prognostic factors associated with improved outcome of Escherichia coli bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1997; 16:125-134
42. Harbarth S, Garbino J, Pugin J, et al: Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005; 24:688-690
43. Siegman-Igra Y, Ravona R, Primerman H, et al: Pseudomonas aeruginosa bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2:211-215
44. Gullberg RM, Homann SR, Phair JP: Enterococcal bacteremia: Analysis of 75 episodes. Rev Infect Dis 1989; 11:74-85
45. Leibovici L, Paul M, Poznanski O, et al: Monotherapy versus beta-lactam-aminoglycoside combination treatment for gramnegative bacteremia: A prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-1133
46. Heyland DK, Dodek P, Muscedere J, et al: Randomized trial of monotherapy for the empiric treatment of suspected ventilatorassociated pneumonia. Crit Care Med 2008; 36:737-744
47. Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842
48. Dupont H, Carbon C, Carlet J: Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother 2000; 44:2028-2033
49. Paterson DL, Ko WC, Von Gottberg A, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-37
50. Kim BN, Ryu J, Kim YS, et al: Retrospective analysis of clinical and microbiological aspects of Klebsiella oxytoca bacteremia over a 10-year period. Eur J Clin Microbiol Infect Dis 2002; 21:419-426
51. Fernandez-Guerrero M, Gudiol F, Rodriguez-Torres A, et al: Nosocomial pneumonia: Comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection 1991; 19(Suppl 6):S320-S325
52. Kuikka A, Valtonen VV: Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701-708
53. Piccart M, Klastersky J, Meunier F, et al: Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 1984; 26:870-875
54. Bodey GP, Jadeja L, Elting L: Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621-1629
55. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al: Optimal management therapy for Pseudomonas aeruginosa ventilatorassociated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888-1895
56. Chamot E, Boffi EA, Rohner P, et al: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756-2764
57. Kljucar S, Heimesaat M, von Pritzbuer E, et al: Ceftazidim mit und ohn tobramycin versus azlocillin plus tobramycin in der therapie bronchopulmonaler infektionen bei intensivpatienten. Infection 1987; 15: S185-S191
58. Kljucar S, Heimesaat M, van Pritzbuer E, et al: Comparative clinical trial with ceftazidime (CAZ) versus Ceftazidime plus tobramycin (TOB) versus azlocillin (AZL) plus tobramycin in ventilated patients with nosocomial lower respiratory tract infection (LRTI). Proceedings of the 30th International Conference on Antimicrobial Agents and Chemotherapy. 1990; 953
59. D'Antonio D, Fioritoni G, Iacone A, et al: Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empiric treatment of infections in patients with altered host defense: Microbiological and clinical evaluation. Chemotherapy 1992; 28:420-427
60. Hilf M, Yu VL, Sharp J, et al: Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-546
61. Watanakunakorn C, Patel R: Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin. Clin Infect Dis 1993; 17:74-78
62. Klastersky J, Cappel R, Daneau D: Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer 1973; 31:331-336
63. Montgomerie JZ, Ota JK: Klebsiella bacteremia. Arch Intern Med 1980; 140:525-527
64. Graninger W, Ragette R: Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992; 15:49-57
65. Ko WC, Lee HC, Chuang YC, et al: Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect 2000; 40:267-273
66. Aspa J, Rajas O, Rodriguez DC, et al: Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27:1010-1019
67. Fainstein V, Bodey GP, Elting L, et al: A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 1983; 12(Suppl 10): 101-110
68. Maki DG, Agger WA: Enterococcal bacteremia: Clinical features, the risk of endocarditis, and management. Medicine 1988; 67: 248-269
69. Mendelson MH, Gurtman A, Szabo S, et al: Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994; 18: 886-895
70. Bodey GP, Elting LS, Rodriquez S, H et al: Klebsiella bacteremia: A 10-year review in a cancer institution. Cancer 1989; 64: 2368-2376
71. Feldman C, Smith C, Levy H, et al: Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect 1990; 20:21-31
72. Tapper ML, Armstrong D: Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: A progress report. J Infect Dis 1974; 130:S14-S23
73. Hammond JM, Potgieter PD, Linton DM, et al: Intensive care management of community-acquired Klebsiella pneumonia. Respir Med 1991; 85:11-16
74. de la Torre G, Romero-Vivas J, Martinez-Beltran J, et al: Klebsiella bacteremia: An analysis of 100 episodes. Rev Infect Dis 1985; 7:143-150
75. Fowler RA, Flavin KE, Barr J, et al: Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003; 123:835-844, 2003
76. Gleason PP, Meehan TP, Fine JM, et al: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-2572
77. Dudas V, Hopefl A, Jacobs R, et al: Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34:446-452
78. Paul M, Nielsen AD, Gafter-Gvili A, et al: The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 2007; 30:525-531
79. Krumpe PE, Cohn S, Garreltes J, et al: Intravenous and oral mono-or combinationtherapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy Ciprofloxacin Study Group. J Antimicrob Chemother 1999; 43(Suppl A):117-128
80. Weiss K, Low DE, Cortes L, et al: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11:589-593
81. Korvick JA, Peacock JE Jr, Muder RR, et al: Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: Prospective trial using the Zelen protocol. Antimicrobial Agents Chemother 1992; 36:620-625
82. Higgins JP, Thompson SG: Controlling the risk of spurious findings from metaregression. Stat Med 2004; 23:1663-1682
83. Thompson SG, Smith TC, Sharp SJ: Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 1997; 16:2741-2758
84. Rello J, Lisboa T, Lujan M, et al: Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136: 832-840
85. Ovstebo R, Brandtzaeg P, Brusletto B, et al: Use of robotized DNA isolation and realtime PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 2004; 42:2980-2987
86. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596
87. Kumar A, Haery C, Paladugu B, et al: The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: Association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006; 193:251-258
88. Comber KR, Basker MJ, Osborne CD, et al: Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother 1977; 11: 956-964
89. Archer G, Fekety FR Jr: Experimental endocarditis due to Pseudomonas aeruginosa II. Therapy with carbenicillin and gentamicin. J Infect Dis 1977; 136:327-335
90. Yoshikawa TT, Shibata SA: In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa. Antimicrob Agents Chemother 1978; 13:997-999
91. Kluge RM, Standiford HC, Tatem B, et al: Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrobial Agents Chemother 1974; 6:442-446
92. Gimeno C, Borja J, Navarro D, et al: In vitro interaction between ofloxacin and cefotaxime against gram-positive and gramnegative bacteria involved in serious infections. Chemotherapy 1998; 44:94-98
93. Gradelski E, Kolek B, Bonner DP, et al: Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 2001; 17: 103-107
94. Zembower TR, Noskin GA, Postelnick MJ, et al: The utility of aminoglycosides in an era of emerging drug resistance. Int J Antimicrob Agents 1998; 10:95-105
95. Neu HC: Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 1993; 45(Suppl-3):54-58
96. Pohlman JK, Knapp CC, Ludwig MD, et al: Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. Diagn Microbiol Infect Dis 1996; 26:29-33
97. Milatovic D, Wallrauch C: In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Eur J Clin Microbiol Infect Dis 1996; 15: 688-693
98. Pankuch GA, Lin G, Seifert H, et al: Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 333-336
99. MacGowan AR, Bowker K, Bedford KA, et al: Synergy testing of macrolide combinations using the chequerboard technique. J Antimicrob Chemother 1993; 32:913-915 1
100. Furuya R, Nakayama H, Kanayama A, et al: In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12: 172-176 1
101. Maioli E, Debbia EA, Gualco L, et al: In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa. New Microbiol 2008; 31: 37-46 1
102. Allen NE, Epp JK: Mechanism of penicillinerythromycin synergy on antibiotic-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13:849-853 1
103. Gogos CA, Drosou E, Bassaris HP, et al: Proversus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J Infect Dis 2000; 181:176-180 1
104. Oberholzer A, Souza SM, Tschoeke SK, et al: Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005; 23:488-493 1
105. Guchelaar HJ, Schultz MJ, van D, et al: Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. Fund Clin Pharmacol 2001; 15:419-424 1
106. Labro MT: Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Micro Rev 2000; 13:615-650 1
107. Labro MT: Cellular and molecular effects of macrolides on leukocyte function. Curr Pharma Design 2004; 10:3067-3080 1
108. Khan AA, Slifer TR, Araujo FG, et al: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-132 1
109. Oda H, Kadota J, Kohno S, et al: Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106:1116-1123 1
110. Pasquale TR, Tan JS: Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40:127-135 1
111. Khan AA, Slifer TR, Remington JS: Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother 1998; 42:1713-1717 1
112. Acar JF: Antibiotic synergy and antagonism. Med Clin North Am 2000; 84:1391-1406 1
113. Tillotson JR, Finland M: Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis 1969; 119:597-624